Bromazepam Stats & Data

Bromazepam was developed by the Swiss pharmaceutical company Roche, receiving its patent in 1961. The compound was subsequently approved for medical use in 1974, entering the pharmaceutical market as an intermediate-acting anxiolytic medication. Like other benzodiazepines, bromazepam carries recognized concerns regarding misuse and diversion. Research conducted in France examining motor vehicle accidents involving psychotropic substances found that benzodiazepines—particularly diazepam, nordiazepam, and bromazepam—were among the most frequently detected drugs in drivers' blood when combined with alcohol. The substance has also been documented in connection with serious criminal activities, including cases of robbery, homicide, and sexual assault.

Bromazepam has a low toxicity relative to dose. However, it is potentially lethal when mixed with depressants like alcohol or opioids. It is strongly recommended that one use harm reduction practices.

Effects aggregated from 18 experience reports (18 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 18 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Also reported in combinations. In the 7 Bromazepam reports where another drug was taken too, 0 mention hospital, emergency services or an overdose, 0 a seizure and 1 psychosis (too few reports for percentages). In the 18 single-substance reports: 1, 0 and 0. These are not in the figures above: they cannot be put down to Bromazepam alone, and a mention is not always something that happened to the writer.

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

From 23 of 25 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 25 reports filed under Bromazepam; whiskers are 95% intervals

Most common forms and preparations, as a share of the 19 reports that give one

Too few reports for bars: these forms come from 19 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• Pill / Tablet 19 of 19

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Redosing behavior across 21 reports